Urogen Pharma Ltd（URGN）股票分析URGNUrogen Pharma Ltd

UroGen Pharma Ltd. Is an Israel-based biopharmaceutical company. The Company is engaged in building solutions for cancers and urologic diseases. UroGen has developed RTGelTM reverse-thermal hydrogel, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs. Its lead product candidates include MitoGel and VesiGel are formulated using its proprietary reverse thermally triggered hydrogel, or RTGel, technology. MiroGel ( UGN-101) is a sustained release formulation of the chemotherapy agent Mitomycin C for the treatment of low-grade upper tract urothelial carcinoma, an urothelial cancer in the upper tract. VesiGel (UGN-102) is a sustained release formulation of a high dose Mitomycin C for the treatment of low grade non-muscle invasive bladder cancer (LG-NMIBC). It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

UroGen Pharma is currently a hold. The stock is trading at $34.49, significantly below the average analyst price target of $60, suggesting potential for upside. However, the RSI is at 28.721, indicating that the stock is oversold, which could mean further downside risk. Additionally, the forward P/E ratio is 36.4964, suggesting that the stock may be overvalued based on future earnings expectations. The recent FDA acceptance of UGN-103 for bladder cancer treatment is a positive catalyst, but the stock has seen a decline of 16.59% over the past 20 days, indicating market caution. The main risk is the high forward P/E ratio, which may not justify the current price if future earnings do not meet expectations.

4 analysts cover URGN: 3 rate it Buy, 1 Hold and 0 Sell. The average price target is 40.25.